期刊
CLINICAL NEUROLOGY AND NEUROSURGERY
卷 107, 期 5, 页码 355-360出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.clineuro.2004.12.002
关键词
prion disease; 14-3-3 protein; tau protein; amyloid-beta; variant CJD; sporadic CJD; differential diagnosis
Creutzfeldt-Jakob disease (CJD) is a rare neurodegenerative disorder. Since the emergence of variant CID (vCJD) vigilance concerning the disease's incidence has increased and the interest in accurate in vivo diagnosis has augmented. So far, a large number of biomarkers has been investigated as aid in the differential diagnosis of sporadic Creutzfeldt-Jakob disease (sCJD) and vCJD. These include, among others, neuron-specific enolase (NSE), microtubuli associated protein Tau, S-100 beta, amyloid-beta (A beta(1-42)) and the 14-3-3 protein. Multiple studies have confirmed that CSF detection of 14-3-3 protein by Western blot was the best single biomarker for sCJD with an average sensitivity and specificity of 92%. Also, in genetic and iatrogenic CJD (iCJD) patients with an average disease duration of less than 1 year, 14-3-3 is the best differential biomarker. Unfortunately, the 14-3-3 protein has a lower sensitivity if the disease duration exceeds beyond I year in both sporadic CID and other CJD types (vCJD, and specific genetic or iatrogenic CJD types). (c) 2004 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据